genedrive plc is a molecular diagnostics company developing and commercialising a low-cost, rapid, versatile, simple to use and robust point of need molecular platform for the diagnosis of infectious diseases, and for use in patient stratification (genotyping), pathogen detection and other indications. We are passionate about the opportunity to build a sustainable business around molecular diagnostics and to play an important role in the diagnostic and treatment challenges presented by global health issues. Genedrive® development has been validated through a range of applications and external independent evaluations. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and the Asia Pacific region. The company has an active development programme underway for tuberculosis detection and drug resistance assessment. The company most recently announced the launch of the Genedrive MT-RNR1 ID Kit, a pharmacogenomic test to prevent antibiotic induced deafness in infants, which is being co-developed with the partners in the UK's National Health Service. The company released a high throughput SARS-CoV-2 assay in 2020, Genedrive 96 SARS-CoV-2, and has recently launched a rapid point of care test for COVID-19 for use on the Genedrive instrument, the Genedrive COV19-ID Kit.